Search

Nadolol

[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and … [A34177] Nadolol was granted FDA approval on 10 December 1979.[L7922]

Vamorolone

[L48671,L48676] In December 2023, it was approved in the EU for the treatment of patients ≥4 years of age.[L49505] … It is used to manage inflammation and immune dysregulation in patients with Duchenne muscular dystrophy (DMD), a neuromuscular disorder characterized by the insidious regression of neuromuscular function

Indocyanine green acid form

The chemical name for Indocyanine Green is 1 H-Benz[e]indolium, 2-[7-[1,3-dihydro-1,1-dimethyl-3-(4-sulfobutyl)-2H-benz[e] indol-2-ylidene]-1,3,5-heptatrienyl]-1,1-dimethyl-3-(4-sulfobutyl)-,hydroxide, … Each vial of Indocyanine Green for Injection USP contains 25 mg of Indocyanine Green as a sterile lyophilized powder with no more than 5% sodium iodide.

Evening primrose oil

In its composition it presents some fatty acids such as [DB00132] and [DB13854]. … Evening primrose oil comes from the extraction from _Oenothera biennis_ seeds and it is commonly used as an alternative source for omega-6 essential fatty acids.

Sodium glycerophosphate

It is used clinically to treat or prevent low phosphate levels [FDA Label]. Glycerophosphate is hydrolyzed to inorganic phosphate and glycerol in the body [A32667]. … The extent of this reaction is dependent on the activity of serum alkaline phosphatases.

Zinc acetate

AMG 108

AMG 108 was investigated for use as an antirheumatic agent.

Ataluren

This drug does not yet have approval by the US Food and Drug Administration or by Health Canada for any indications. … More specifically, ataluren is used in the small group of patients whose disease is caused by a specific genetic defect (called a ‘nonsense mutation’) in the dystrophin gene.

Lisocabtagene maraleucel

[A228493] Lisocabtagene maraleucel was granted FDA approval on 5 February 2021 [L31583] and EC approval on 5 April 2022.[L42210] It was later granted Health Canada approval on 6 May 2022. … [A228493] However, data on the efficacy of CAR T-cell therapies on less severe forms of B-cell lymphoma are lacking.

Miltefosine

The CDC has also recommended it as a first line treatment for free-living amebae (FLA) infections such as primary amebic meningoencephalitis and granulomatous amebic encephalitis. … It can be administered topically or orally and is only indicated in patients aged 12 years or older.